Study of response of axillary lymph nodal metastases toneoadjuvant chemotherapy in carcinoma breast
Keywords:
pathological response, axillary lymph nodes, neoadjuvant chemotherapyAbstract
Background and aim of the study: Our study aims to evaluate pathological response in axillary lymph nodes with neoadjuvant chemotherapy. Absence of invasive disease in breast and axilla after completion of neoadjuvant chemotherapy on histological examination was taken as pathological complete response (pCR). Absence of invasive disease in axilla after completion of chemotherapy on histological examination was taken as pathological complete response in axilla. Materials and Methods: A prospective observational study was conducted on breast cancer patients who were treated at MNJ Institute of Oncology and Regional Cancer Centre for a period of 22 months. A total of 55 with operable breast cancer and cytologically proven axillary lymph node metastases and subsequently received neoadjuvant chemotherapy were considered for this study. All these patients were registered in our hospital and were followed prospectively. Of them, 2 patients defaulted chemotherapy, 3 patients did not visit hospital after completion of chemotherapy and 1patient died due to reason other than carcinoma breast and all these patients were excluded from the study. Results:In this study, we had pathological complete response in breast and axilla in 24.5% of the study population.
Downloads
References
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ. Comparison of sentinellymphnodebiopsyalone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009 Jun 20;27(18):2946-53.
Boughey JC, Suman VJ, Mittendorf EA, Ahrendt GM, Wilke LG, Taback B, Leitch AM, Kuerer HM, Bowling M, Flippo-Morton TS, Byrd DR, Ollila DW, Julian TB, McLaughlin SA, McCall L, Symmans WF, Le-Petross HT, Haffty BG, Buchholz TA, Nelson H, Hunt KK; Alliancefor Clinical Trialsin Oncology. Sentinellymphnodesurgeryafterneoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013 Oct 9;310(14):1455-61.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424.
BuzdarAU,IbrahimNK,FrancisD,BooserDJ,ThomasES,TheriaultRL,PusztaiL,Green MC, Arun BK, Giordano SH, Cristofanilli M, Frye DK, Smith TL, Hunt KK, Singletary SE, SahinAA,EwerMS,BuchholzTA,BerryD,HortobagyiGN.Significantlyhigherpathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1;23(16):3676-85.
CortazarP,ZhangL,UntchM,MehtaK,CostantinoJP,WolmarkN,BonnefoiH,Cameron D, Gianni L, Valagussa P, Swain SM, Prowell T, Loibl S, Wickerham DL, Bogaerts J, BaselgaJ,PerouC,BlumenthalG,BlohmerJ,MamounasEP,BerghJ,SemiglazovV,Justice R, Eidtmann H, Paik S, Piccart M, Sridhara R, Fasching PA, Slaets L, Tang S, Gerber B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-72.
Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, BabieraGV,Meric-BernstamF,HuntKK,KuererHM.Cytologicallyprovenaxillarylymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrenttrastuzumabforHER2-positivebreastcancer.Cancer.2010Jun15;116(12):2884- 9.
Giuliano, A.E., Morrow, M., Duggal, S. et al. Should ACOSOG Z0011 change practice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis 29, 687–692 (2012).
Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, FornageB,SahinA,BroglioK,SingletarySE,ValeroV.Outcomeafterpathologiccomplete eradicationofcytologicallyprovenbreastcanceraxillarynodemetastasesfollowingprimary chemotherapy. J Clin Oncol. 2005 Dec 20;23(36):9304-11.
HoussamiN,MacaskillP,vonMinckwitzG,MarinovichML,MamounasE.Meta-analysis of the association of breast cancer subtype and pathologic complete response toneoadjuvant chemotherapy. Eur J Cancer. 2012 Dec;48(18):3342-54
Kaufmann M, von Minckwitz G, Bear HD, Buzdar A, McGale P, Bonnefoi H, Colleoni M, Denkert C, Eiermann W, Jackesz R, Makris A, Miller W, Pierga JY, Semiglazov V, Schneeweiss A, Souchon R, Stearns V, Untch M, Loibl S. Recommendations from an internationalexpertpanelontheuseofneoadjuvant(primary)systemictreatmentofoperable breast cancer: new perspectives 2006. Ann Oncol. 2007 Dec;18(12):1927-34.
Kim WH, Kim HJ, Park HY, Park JY, Chae YS, Lee SM, Cho SH, Shin KM, Lee SY. Axillary Pathologic Complete Response to Neoadjuvant Chemotherapy in Clinically Node- Positive Breast Cancer Patients: A Predictive Model Integrating the Imaging Characteristics of Ultrasound Restaging with Known Clinicopathologic Characteristics. Ultrasound Med Biol.2019Mar;45(3):702-709.
Mamounas EP. Impact of neoadjuvant chemotherapy on locoregional surgical treatment of breast cancer. Ann Surg Oncol. 2015 May;22(5):1425-33.
Raidanti, D., Wijayanti, R., & Wahidin, W. (2021). Influence of health counseling with media leaflets on women of childbearing age (WUS): Knowledge and attitude to conduct PAP smear at midwifery poly in RSPAD Gatot Soebroto Jakarta. International Journal of Health & Medical Sciences, 4(3), 362-366. https://doi.org/10.31295/ijhms.v4n3.1777
Spring LM, Fell G, Arfe A, Sharma C, Greenup R, Reynolds KL, Smith BL, Alexander B, Moy B, Isakoff SJ, Parmigiani G, Trippa L, Bardia A. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis. Clin Cancer Res. 2020 Jun 15;26(12):2838-2848.
Subbiah S, Gopu G, Senthilkumar P, Muniasamy P. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. Indian J Cancer. 2017 Oct- Dec;54(4):652-657.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2021). Health and treatment of diabetes mellitus. International Journal of Health Sciences, 5(1), i-v. https://doi.org/10.53730/ijhs.v5n1.2864
VilaJ,MittendorfEA,FaranteG,BassettRL,VeronesiP,GalimbertiV,PeradzeN,Stauder MC, Chavez-MacGregor M, Litton JF, Huo L, Kuerer HM, Hunt KK, Caudle AS. Nomograms for Predicting Axillary Response to Neoadjuvant Chemotherapy in Clinically Node-Positive Patients with Breast Cancer. Ann Surg Oncol. 2016 Oct;23(11):3501-3509.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
